GlaxoSmithKline Pharmaceuticals Limited (GLAXO)

2,343.15

INR
-58.65(-2.44%)
As of December 6, 2024 10:00:00 AM

GlaxoSmithKline Pharmaceuticals Limited Share Price Information

24 hour Low and High

Low: 2361.05
High: 2401.3

All time High

5704.76

Price Change 1h

+₹-58.65 +-2.44%

Price Change 1d

+₹-58.65 +-2.44%

Price Change 1w

+₹-114.00 +-4.64%

GlaxoSmithKline Pharmaceuticals Limited Market Information

Exchange

NSE

Market Cap

45305.00 Cr

About GlaxoSmithKline Pharmaceuticals Limited Share

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines comprising NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and TRELEGY ELLIPTA for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, which are antibiotics to treat bacterial infections; CALPOL for treatment of mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment and prevention of specific bacterial skin infections; BETNOVATE for skin conditions which require relief of inflammation; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin and dry skin associated with redness and itch. Further, it develops products for infectious diseases, HIV, oncology, and immunology. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.

Sector

Healthcare

Drug Manufacturers - General

Employees

about

3211

CEO

Revenue (2023)

%

Country of Origin

India

Key Highlights

  • GSK Pharma stock gains over 3% after profit, revenue boost in Q2 earnings
  • Glaxosmithkline Pharmaceuticals Ltd sees -4.0% decline in stock price, underperforms sector
  • Stocks in news: General Insurance Corp, ONGC, SpiceJet, GSK Pharma, Cipla
  • Public companies account for 75% of GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) ownership, while individual investors account for 18%
  • GlaxoSmithKline Pharma gets big income tax refund

FAQs

GlaxoSmithKline Pharmaceuticals Limited (GLAXO)

2,343.15

INR
-58.65(-2.44%)
As of December 6, 2024 10:00:00 AM

GlaxoSmithKline Pharmaceuticals Limited Share Price Information

24 hour Low and High

Low: 2361.05
High: 2401.3

All time High

5704.76

Price Change 1h

+₹-58.65 +-2.44%

Price Change 1d

+₹-58.65 +-2.44%

Price Change 1w

+₹-114.00 +-4.64%

GlaxoSmithKline Pharmaceuticals Limited Market Information

Exchange

NSE

Market Cap

45305.00 Cr

About GlaxoSmithKline Pharmaceuticals Limited Share

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines comprising NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and TRELEGY ELLIPTA for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, which are antibiotics to treat bacterial infections; CALPOL for treatment of mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment and prevention of specific bacterial skin infections; BETNOVATE for skin conditions which require relief of inflammation; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin and dry skin associated with redness and itch. Further, it develops products for infectious diseases, HIV, oncology, and immunology. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.

Sector

Healthcare

Drug Manufacturers - General

Employees

about

3211

CEO

Revenue (2023)

%

Country of Origin

India

Key Highlights

  • GSK Pharma stock gains over 3% after profit, revenue boost in Q2 earnings
  • Glaxosmithkline Pharmaceuticals Ltd sees -4.0% decline in stock price, underperforms sector
  • Stocks in news: General Insurance Corp, ONGC, SpiceJet, GSK Pharma, Cipla
  • Public companies account for 75% of GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) ownership, while individual investors account for 18%
  • GlaxoSmithKline Pharma gets big income tax refund

FAQs